Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: A systematic review

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Thirugnanam, Subarna ^a   Pinto, Ruxandra ^b   Cook, Deborah J ^c   Geerts, William H ^d   Fowler, Robert A ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BEMIPARIN; DABIGATRAN; DALTEPARIN; DERMATAN SULFATE; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RIVAROXABAN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT; POLYSACCHARIDE;

ARTICLE; BLEEDING; COMPRESSION GARMENT; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; PREVENTION STUDY; PRIORITY JOURNAL; SURGICAL PATIENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; COST BENEFIT ANALYSIS; ECONOMICS; PRACTICE GUIDELINE;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; POLYSACCHARIDES; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84857929499     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11241     Document Type: Article

References (63)

1. Geerts W, Pineo G, Heit J, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism: The Seventh ACCP conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:338S-400S. 10.1378/chest.126.3_suppl.338S, 15383478.
2. Cook D, Crowther M, Meade M, Douketis J. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005, 12:309-313.
3. Kakkar V, Flanc C, Howe C. Natural history of postoperative deep vein thrombosis. Lancet 1969, 2:230-234.
4. Barritt D, Jordan S. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960, 1:1309-1312.
5. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991, 78:849-852. 10.1002/bjs.1800780725, 1873716.
6. Patel R, Cook DJ, Meade MO, Griffith LE, Mehta G, Rocker GM, Marshall JC, Hodder R, Martin CM, Heyland DK, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH, . for the Burden of Illness in Venous Thrombo Embolism in Critical Care (BITEC) Study Investigators; Canadian Critical Care Trials Group Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005, 20:341-347. 10.1016/j.jcrc.2005.09.014, 16310605, for the Burden of Illness in Venous Thrombo Embolism in Critical Care (BITEC) Study Investigators; Canadian Critical Care Trials Group.
7. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ, . Evidence Report/Technology Assessment Number 43 Making health care safer: a critical analysis of patient safety practices: summary. Evidence Report/Technology Assessment Number 43., http://www.ahrq.gov/clinic/ptsafety/summary.htm
8. Olin G, Machlin R, , . Agency for Healthcare Research and Quality, Center for Cost and Financing Studies Health care expenses in the US civilian population Agency for Healthcare Research and Quality, Center for Cost and Financing Studies., http://www.meps.ahrq.gov/papers/rf_01-r035/statisticaltables.htm
9. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF. User's guide to the medical literature: XIII, How to use an article on economic analysis of clinical practice: B, What are the results and will they help me in caring for my patients?. JAMA 1997, 277:1802-1814. 10.1001/jama.1997.03540460066034, 9178794.
10. Chau Q, Cantor S, Caramel E. Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep venous thrombosis of the lower extremities. Support Care Cancer 2003, 11:795-799. 10.1007/s00520-003-0520-2, 13680322.
11. Epstein N. Intermittent pneumatic compression stocking prophylaxis against deep venous thrombosis in anterior cervical spinal surgery: a prospective efficacy study in 200 patients and literature review. Spine 2005, 30:2538-2543. 10.1097/01.brs.0000186318.80139.40, 16284592.
12. Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996, 109:82-85. 10.1378/chest.109.1.82, 8549224.
13. Sing R, Smith C, Miles W, Messick WJ. Preliminary results of bedside inferior vena cava filter placement: safe and cost-effective. Chest 1998, 114:315-316. 10.1378/chest.114.1.315, 9674486.
14. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement: a prospective, randomized trial. J Bone Joint Surg 1998, (80B):1158-1166.
15. Williams J, Palfrey S. Cost effectiveness and efficacy of below knee against above knee graduated compression stockings in the prevention of deep vein thrombosis. Phlebologie 1988, 41:809-811.
16. Woolson S. Intermittent pneumatic compression prophylaxis for proximal deep venous thrombosis after total hip replacement. J Bone Joint Surg 1996, 78:1735-1740.
17. Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoS Med 2009, 6:e1000098. 10.1371/journal.pmed.1000098, 2695771, 19554085.
18. Gross domestic product deflator inflation calculator. , http://cost.jsc.nasa.gov/inflateGDP.html
19. Universal currency converter. , http://www.xe.com/ucc/
20. Pechevis M, Detournay B, Pribil C, Fagnani F, Chalanson G. Economic evaluation of enoxaparin versus placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health 2000, 3:389-396. 10.1046/j.1524-4733.2000.36008.x, 16464198.
21. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econ 2001, 4:99-113.
22. Lamy A, Wang X, Kent R, Smith KM, Gafni A. Economic evaluation of the MEDENOX trial: a Canadian perspective: medical patients with enoxaparin. Can Respir J 2002, 9:169-177.
23. Offord R, Lloyd A, Anderson P, Bearne A. Economic evaluation of enoxaparin for the prevention of venous thrombosis in acutely ill medical patients. Pharm World Sci 2004, 26:214-220.
24. Schadlich P, Kentsch M, Weber M. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modeling study from the hospital perspective in Germany. Pharmacoeconomics 2006, 24:571-591. 10.2165/00019053-200624060-00005, 16761905.
25. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994, 81:1742-1746. 10.1002/bjs.1800811212, 7827928.
26. Hawkins D, Langley C, Krueger K. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health Syst Pharm 1997, 54:1185-1190.
27. Marchetti M, Liberato N, Ruperto N, Barosi G. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica 1999, 84:730-737.
28. Etchells E, McLeod R, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 1999, 159:1221-1228. 10.1001/archinte.159.11.1221, 10371230.
29. McGarry L, Thompson D, Weinstein M, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 2004, 10:632-642.
30. Lloyd A, Aitken JA, Hoffmeyer UK, Kelso EJ, Wakerly EC, Barber ND. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. Pharmacoeconomics 1997, 12:475-485. 10.2165/00019053-199712040-00005, 10174313.
31. Heerey A, Suri S. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. Pharmacoeconomics 2005, 23:927-944. 10.2165/00019053-200523090-00005, 16153135.
32. Wade WE, Spruill WJ. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery. Am J Ther 2008, 15:512-515. 10.1097/MJT.0b013e3181727aa0, 19127133.
33. Deitelzweig SB, Becker R, Lin J, Benner J. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost 2008, 100:810-820.
34. O'Brien B, Anderson D, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ 1994, 150:1083-1090. 1486381, 8137188.
35. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995, 155:757-764. 10.1001/archinte.1995.00430070117013, 7695464.
36. Hull R, Raskob G, Pineo G. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: an economic perspective. Arch Intern Med 1997, 157:298-303. 10.1001/archinte.1997.00440240060009, 9040296.
37. Hawkins D, Langley P, Krueger K. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 1998, 20:182-195. 10.1016/S0149-2918(98)80045-3, 9522114.
38. Botteman M, Caprini J, Stephens J. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther 2002, 24:1960-1986. 10.1016/S0149-2918(02)80091-1, 12501885.
39. Nerurkar J, Wade W, Martin B. Cost/Death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or arthroplasty. Pharmacotherapy 2002, 22:990-1000. 10.1592/phco.22.12.990.33609, 12173802.
40. Francis CW, Pleil AM, Reinhart SP. A pharmacoeconomic evaluation of low-molecular-weight heparin in patients after total hip-replacement surgery. P and T 1999, 24:136-145.
41. Caprini JA, Arcelus JI, Kudrna JC, Sehgal LR, Oyslender M, Maksimovic D, MacDougall A. Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement. Phlebology 2002, 17:126-133.
42. Levin L, Bergqvist D. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery. Pharmacoeconomics 2001, 19:589-597. 10.2165/00019053-200119050-00012, 11465303.
43. Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 2004, 22:885-894. 10.2165/00019053-200422130-00006, 15329033.
44. Attanasio E, Russo P, Carunchio G, Caprino L. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics 2001, 19:57-68.
45. Wade W, Spruill W. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data. Blood Coagul Fibrinol 2001, 12:619-625.
46. Gordois A, Posnett J, Borris L. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003, 1:2167-2174. 10.1046/j.1538-7836.2003.00396.x, 14521600.
47. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur J Health Econ 2003, 4:254-262. 10.1007/s10198-003-0175-4, 15609193.
48. Wade E, Spruill W, Leslie R. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am J Orthop 2003, 4:201-206.
49. Annemans L, Minjoulat-Rey M, De Knock M. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery in Belgium. Acta Clin Belg 2004, 59:346-357.
50. Dranitsaris G, Kahn S, Stumpo C. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs 2004, 4:325-333. 10.2165/00129784-200404050-00005, 15449974.
51. Spruill W, Wade W, Leslie R. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 2004, 11:3-8. 10.1097/00045391-200401000-00004, 14704589.
52. Spruill W, Wade W, Leslie R. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery. Blood Coagul Fibrinol 2004, 15:539-543.
53. Wade W, Spruill W, Leslie R. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery. Am J Ther 2004, 11:194-198. 10.1097/00045391-200405000-00007, 15133534.
54. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs 2005, 5:121-130. 10.2165/00129784-200505020-00006, 15725043.
55. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 2004, 22:605-620. 10.2165/00019053-200422090-00005, 15209529.
56. Szucs TD, Kaiser WE, Mahler F, Gutzwiller F. Thromboembolic prophylaxis with fondaparinux in major orthopaedic surgery: outcomes and costs. Heart Drug 2005, 5:121-130.
57. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009, 27:829-846. 10.2165/11313800-000000000-00000, 19803538.
58. Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009, 31:194-212. 10.1016/j.clinthera.2009.01.001, 19243718.
59. Merli G, Ferrufiono C, Lin M, Hussein M, Battleman D. Hospital-based costs associated with venous thromboembolism treatment regimens. J Thromb Haemost 1996, 6:1077-1086.
60. Kelly R, Cohen L, Semple R. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 2006, 36:1647-1657. 10.1017/S0033291706008567, 16893480.
61. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Family Prac 2001, 18:565-568.
62. Goeree R, Burke N, O'Reilly D, Manca A, Blackhouse G, Tarride JE. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007, 23:671-682. 10.1185/030079906X167327, 17407623.
63. Robb P, Freer J, Seddon J, Young J, . for the National Institute for Health and Clinical Excellence Venous thromboembolism prophylaxis guidelines, April 2007 for the National Institute for Health and Clinical Excellence., http://www.nice.org.uk/